Home › Overweight › Arizona › Tucson
Pag-aaral pangklinika para sa Overweight sa Tucson, AZ
Isang pag-aaral para sa Overweight ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Tucson. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Nagre-recruitPhase 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Nagre-recruitPhase 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Nagre-recruitPhase 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Nagre-recruitPhase 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Nagre-recruitPhase 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Nagre-recruitPhase 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Nagre-recruitPhase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Nagre-recruitPhase 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Nagre-recruitPhase 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Nagre-recruitPhase 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Nagre-recruitPhase 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Nagre-recruitPhase 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Nagre-recruitPhase 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Nagre-recruitPhase 3
- ACCOMPLISH-1 Research Site, Tucson
Pag-aaral para sa Overweight sa ibang lungsod
- San Antonio, TX34 pag-aaral
- Houston, TX33 pag-aaral
- Chicago, IL28 pag-aaral
- Orlando, FL27 pag-aaral
- Las Vegas, NV23 pag-aaral
- Miami, FL23 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX20 pag-aaral
- New York City, NY19 pag-aaral
- Jacksonville, FL19 pag-aaral
- Washington, DC19 pag-aaral
- Austin, TX18 pag-aaral
Iba pang pag-aaral sa Tucson
- Kanser sa Suso20 pag-aaral
- Non-Small Cell Lung Cancer17 pag-aaral
- Obesity17 pag-aaral
- Metastatic Cancer14 pag-aaral
- Kanser (lahat ng uri)12 pag-aaral
- Sakit sa Puso at Ugat ng Dugo12 pag-aaral
- Colorectal Cancer11 pag-aaral
- Kanser sa Prostate11 pag-aaral
- Steatotic Liver Disease10 pag-aaral
- Pagkabigo ng Puso10 pag-aaral
- Mataas na Presyon ng Dugo10 pag-aaral
- Type 2 Diabetes10 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.